Hercules Capital 관리

관리 기준 확인 2/4

Hercules Capital CEO는 Scott Bluestein, Apr2014 에 임명되었습니다 의 임기는 10.58 년입니다. 총 연간 보상은 $ 8.89M, 7.3% 로 구성됩니다. 7.3% 급여 및 92.7% 보너스(회사 주식 및 옵션 포함). 는 € 38.52M 가치에 해당하는 회사 주식의 1.34% 직접 소유합니다. 38.52M. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 4.3 년입니다.

주요 정보

Scott Bluestein

최고 경영자

US$8.9m

총 보상

CEO 급여 비율	7.3%
CEO 임기	10.6yrs
CEO 소유권	1.3%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Scott Bluestein 의 보수는 Hercules Capital 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$318m
Jun 30 2024	n/a	n/a	US$278m
Mar 31 2024	n/a	n/a	US$331m
Dec 31 2023	US$9m	US$650k	US$334m
Sep 30 2023	n/a	n/a	US$277m
Jun 30 2023	n/a	n/a	US$302m
Mar 31 2023	n/a	n/a	US$197m
Dec 31 2022	US$7m	US$650k	US$100m
Sep 30 2022	n/a	n/a	US$42m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$105m
Dec 31 2021	US$6m	US$650k	US$172m
Sep 30 2021	n/a	n/a	US$319m
Jun 30 2021	n/a	n/a	US$339m
Mar 31 2021	n/a	n/a	US$318m
Dec 31 2020	US$7m	US$650k	US$226m
Sep 30 2020	n/a	n/a	US$120m
Jun 30 2020	n/a	n/a	US$96m
Mar 31 2020	n/a	n/a	US$83m
Dec 31 2019	US$8m	US$594k	US$173m
Sep 30 2019	n/a	n/a	US$111m
Jun 30 2019	n/a	n/a	US$128m
Mar 31 2019	n/a	n/a	US$132m
Dec 31 2018	US$11m	US$515k	US$76m
Sep 30 2018	n/a	n/a	US$111m
Jun 30 2018	n/a	n/a	US$109m
Mar 31 2018	n/a	n/a	US$90m
Dec 31 2017	US$3m	US$500k	US$78m

보상 대 시장: Scott 의 총 보상 ($USD 8.89M )은 German 시장( $USD 1.97M ).

보상과 수익: Scott 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Scott Bluestein (46 yo)

10.6yrs

테뉴어

US$8,891,994

보상

Mr. Scott Bluestein is Miscellaneous of UBS Securities LLC. He is Chief Executive Officer, Chief Investment Officer, President and Director of Hercules Capital, Inc. He joined the Hercules Capital, Inc. in...

리더십 팀

이름	위치	테뉴어	보상	소유권
Scott Bluestein	CEO, Chief Investment Officer	10.6yrs	US$8.89m	1.34% € 38.5m
Seth Meyer	CFO & Chief Accounting Officer	5.7yrs	US$3.04m	0.21% € 6.0m
Christian Follmann	Chief Operating Officer	8.8yrs	US$1.21m	0.059% € 1.7m
Kiersten Botelho	Corporate Secretary	2.8yrs	US$1.08m	0.029% € 846.4k
Steve Kuo	Senior MD & Group Head of Technology	5.8yrs	데이터 없음	데이터 없음
Michael Hara	Managing Director of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Kate Kinlin	VP of Human Resources	2.6yrs	데이터 없음	데이터 없음
Roy Liu	Managing Director	20.6yrs	데이터 없음	데이터 없음
R. Jadot	Senior MD & Group Head of Life Sciences	5.5yrs	데이터 없음	데이터 없음
Michael Bowden	Managing Director of Portfolio Management	5.8yrs	데이터 없음	데이터 없음
Janice Bourque	Managing Director	14.6yrs	데이터 없음	데이터 없음
Lesya Kulchenko	Managing Director	5.8yrs	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: 19H 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Scott Bluestein	CEO, Chief Investment Officer	5.3yrs	US$8.89m	1.34% € 38.5m
Gayle Crowell	Independent Director	5.8yrs	US$215.00k	0.037% € 1.1m
Robert Badavas	Chairman of the Board & Lead Independent Director	18.7yrs	US$310.00k	0.070% € 2.0m
Pam Randhawa	Independent Director	3yrs	US$250.00k	0.010% € 287.6k
Nikos Theodosopoulos	Independent Director	1.2yrs	US$39.99k	0.0035% € 101.0k
Thomas Fallon	Independent Director	10.3yrs	US$205.00k	0.062% € 1.8m
Wade Loo	Independent Director	3.3yrs	US$215.00k	0.017% € 476.3k
DeAnne Aguirre	Independent Board Directors	2.4yrs	US$145.00k	0.0086% € 247.5k

4.3yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: 19H 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

Hercules Capital 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Hercules Capital, Inc., Annual General Meeting, Jun 20, 2024

Hercules Capital Appoints Nikos Theodosopoulos an Independent Member of its Board of Directors and to Serve on Audit Committee

Independent Director recently bought €89k worth of stock

Independent Director recently bought €89k worth of stock

Hercules Capital, Inc. Announces Resignation of Brad Koenig as Member of the Board

Hercules Capital, Inc. Appoints Deanne Aguirre to its Board of Directors

Recent updates

Third quarter 2024 earnings released: EPS: US$0.43 (vs US$0.19 in 3Q 2023)

Second quarter dividend of US$0.48 announced

Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter 2024, Payable on November 20, 2024

Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million.

KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC).

KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC).

Second quarter 2024 earnings released: EPS: US$0.26 (vs US$0.66 in 2Q 2023)

First quarter dividend of US$0.48 announced

Hercules Capital, Inc. Declares Cash Distribution for the Second Quarter 2024, Payable on August 20, 2024

Hercules Capital, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC completed the acquisition of ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others.

First quarter dividend of US$0.48 announced

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.69 in 1Q 2023)

Hercules Capital, Inc. Declares First Quarter Cash Dividend, Payable on May 14, 2024

Hercules Capital, Inc., Annual General Meeting, Jun 20, 2024

Hercules Capital, Inc. to Report Q1, 2024 Results on May 02, 2024

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.

Upcoming dividend of US$0.48 per share

Full year 2023 earnings released: EPS: US$2.34 (vs US$0.80 in FY 2022)

Hercules Capital, Inc. Declares Cash Distribution for the Fourth Quarter 2023, Dividend Payable on March 6, 2024

Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC entered into an Agreement and Plan of Merger to acquire ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others for approximately $150 million.

Hercules Capital, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Upcoming dividend of US$0.48 per share at 12% yield

Third quarter 2023 earnings released: EPS: US$0.19 (vs US$0.41 in 3Q 2022)

Hercules Capital, Inc. Declares Total Cash Distribution the Third Quarter 2023, Payable on November 22, 2023

Hercules Capital, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New major risk - Revenue and earnings growth

Hercules Capital Appoints Nikos Theodosopoulos an Independent Member of its Board of Directors and to Serve on Audit Committee

Upcoming dividend of US$0.48 per share at 11% yield

Hercules Capital, Inc. has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$0.67 (vs US$0.088 loss in 2Q 2022)

Hercules Capital Declares Cash Distribution for the Second Quarter 2023, Payable August 25, 2023

Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Independent Director recently bought €89k worth of stock

Independent Director recently bought €89k worth of stock

First quarter 2023 earnings released: EPS: US$0.70 (vs US$0.033 loss in 1Q 2022)

Investor sentiment deteriorates as stock falls 20%

Upcoming dividend of US$0.47 per share at 13% yield

Full year 2022 earnings released: EPS: US$0.80 (vs US$1.50 in FY 2021)

Hercules Capital Increases Its Quarterly Cash Distribution for the Fourth Quarter of 2022, Payable on March 9, 2023

Hercules Capital, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Hercules Capital, Inc. Announces Resignation of Brad Koenig as Member of the Board

Third quarter 2022 earnings released: EPS: US$0.42 (vs US$0.20 in 3Q 2021)

Upcoming dividend of US$0.51 per share

Sumitovant Biopharma Ltd. signed an agreement to acquire a 47.83% stake in Myovant Sciences Ltd for $1.2 billion.

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Hercules Capital, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter of 2022, Payable on November 17, 2022

Sumitovant Biopharma Ltd. entered into a non-binding proposal to acquire Myovant Sciences Ltd. (NYSE:MYOV) for $1.2 billion.

Upcoming dividend of US$0.50 per share

Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.71 profit in 2Q 2021)

Hercules Capital, Inc. Increases Quarterly Cash Distribution for the Second Quarter of 2022, Payable on August 16, 2022

Hercules Capital, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Hercules Capital, Inc. Appoints Deanne Aguirre to its Board of Directors

First quarter 2022 earnings released: US$0.028 loss per share (vs US$0.56 profit in 1Q 2021)

Hercules Capital, Inc. Announces Cash Distribution for the First Quarter of 2022, Payable on May 24, 2022

Hercules Capital, Inc., Annual General Meeting, Jun 23, 2022

Hercules Capital, Inc. to Report Q1, 2022 Results on May 05, 2022

Upcoming dividend of US$0.48 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Hercules Capital Declares Cash Distribution for the Fourth Quarter of 2021, Payable on March 16, 2022

Hercules Capital, Inc. to Report Q4, 2021 Results on Feb 22, 2022

Hercules Capital, Inc. Announces Executive Changes

High number of new directors

High number of new directors